Sign In
Buy BCRX
$8.25
-0.0900 (-1.08%)
At Close: Jun 03, 2026
BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 European Academy of Allergy and Clinical Immunology Congress
07:02am, Wednesday, 31'st May 2023
RESEARCH TRIANGLE PARK, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals Inc (Nasdaq: BCRX) today announced that the company will present two abstracts featuring data on oral, once-dail
Why BioCryst Pharmaceuticals Stock Is Soaring Today
01:44pm, Wednesday, 03'rd May 2023
BioCryst Pharmaceuticals reported first-quarter earnings Wednesday morning. The financial report painted an overall encouraging picture regarding its main growth driver, Orladeyo.
BioCryst to Report First Quarter 2023 Financial Results on May 3
07:00am, Wednesday, 19'th Apr 2023
RESEARCH TRIANGLE PARK, N.C., April 19, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2023 financial results on
BioCryst to Present at Upcoming Investor Conferences
07:00am, Wednesday, 12'th Apr 2023
RESEARCH TRIANGLE PARK, N.C., April 12, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the following investor conferences:
BioCryst: Good Candidate For Buyout, But Not For Anything Else
02:01pm, Wednesday, 08'th Mar 2023
BioCryst Pharmaceuticals, Inc. has one blockbuster potential marketed drug, but not much of a pipeline. Last year, they shelved two separate programs for different reasons.
Why Shares of BioCryst Pharmaceuticals Jumped Today
03:29pm, Wednesday, 22'nd Feb 2023
A day after the stock plummeted, it bounced back.
BioCryst Is Not Currently Uncovering The Full Value Of ORLADEYO
09:00am, Wednesday, 22'nd Feb 2023
BioCryst's main value driver, ORLADEYO, is already profitable in its second year on the market and generated over $250 million in revenue in 2022. ORLADEYO is successfully differentiating itself in a
BioCryst to Present at Upcoming Investor Conferences
07:00am, Wednesday, 22'nd Feb 2023
RESEARCH TRIANGLE PARK, N.C., Feb. 22, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the Cowen 43rd Annual Health Care Confer
BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2022 Earnings Call Transcript
01:00pm, Tuesday, 21'st Feb 2023
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Q4 2022 Earnings Conference Call February 21, 2023 8:30 AM ET Company Participants John Bluth - Investor Relations Jon Stonehouse - Chief Executive Office
Why BioCryst Pharmaceuticals Stock Is Sinking Today
11:55am, Tuesday, 21'st Feb 2023
Investors didn't like the drugmaker's Q4 update.
BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates
09:47am, Tuesday, 21'st Feb 2023
BioCryst (BCRX) delivered earnings and revenue surprises of -100% and 6.11%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for BioCryst (BCRX)
12:02pm, Thursday, 16'th Feb 2023
BioCryst (BCRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
BioCryst to Report Fourth Quarter 2022 Financial Results on February 21
07:00am, Tuesday, 07'th Feb 2023
RESEARCH TRIANGLE PARK, N.C., Feb. 07, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2022 financial results on
BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting
07:00am, Friday, 03'rd Feb 2023
RESEARCH TRIANGLE PARK, N.C., Feb. 03, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts featuring data on oral, once
Pharmaceutical Stock Sinks on Sales Forecast
03:10pm, Monday, 09'th Jan 2023
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) stock is sinking today, down 11.6% at $10.45 at last glance, after the company's sales forecast for its skin disease drug, Orladeyo, came in below estimates
